Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study
Clinical Lung Cancer · 2024-06 · 25 (4) · 354-364
DOI: 10.1016/j.cllc.2024.02.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2024-06. Verfasst von Ji Eun Park und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Antibodies, Monoclonal. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Yeungnam University.
Abstract (Originalsprache)
BACKGROUND: The PACIFIC trial demonstrated survival benefit of durvalumab after concurrent chemoradiotherapy (CCRT) in unresectable stage III non-small-cell lung cancer. Data on the effectiveness and safety of durvalumab in elderly patients is lacking. METHODS: This retrospective study was conducted between September 2017 and September 2022. Progression-free survival (PFS), overall survival (OS), recurrence patterns, first subsequent treatment after recurrence, factors associated with survival outcomes, and adverse events (AEs) were compared. RESULTS: Of the 286 patients, 120 (42.0%) were ≥ 70 years and 166 (58.0%) were < 70 years. The median PFS (17.7 vs. 19.4 months; P = .43) and median OS (35.7 months vs. not reached; P = .13) were similar between 2 groups. Proportion of patients who completed durvalumab was lower in elderly patients (27.5% vs. 39.2%; P = .040). In elderly patients, ECOG PS 0 or 1 was associated with better PFS, and being male and having received a cisplatin-based regimen during CCRT were factors associated with better and worse OS, respectively. In patients aged < 70 years, a PD-L1 ≥ 50% was associated with improved PFS and OS. Elderly patients experienced more treatment-related AEs, grade 3/4 AEs, permanent discontinuation of durvalumab, and treatment-related deaths. Among the AEs leading to permanent discontinuation or death, pulmonary AE was significantly more common in elderly patients. CONCLUSION: Durvalumab demonstrated similar outcomes in elderly compared to younger patients. However, AEs were more common in elderly patients. Thus, judicious selection of patients and chemotherapy regimens, coupled with careful AE monitoring, are important factors for ensuring optimal durvalumab treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
- Department of Internal Medicine, School of Medicine, Keimyung University, Busan, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Daegu Catholic University, Daegu, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Republic of Korea.
- Department of Internal Medicine, College of Medicine, Kosin University College of Medicine, Busan, Republic of Korea.
Förderung
- Yeungnam University
Zitieren
APA
Park, J. E., Hong, K. S., Choi, S. H., Lee, S. Y., Shin, K. C., Jang, J. G., Kwon, Y. S., Park, S. H., Choi, K. J., Jung, C. Y., Eom, J. S., Kim, S., Seol, H. Y., Kim, J., Kim, I., Park, J. H., Kim, T. H., & Ahn, J. H. (2024). Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study. Clinical Lung Cancer, 25(4), 354-364. https://doi.org/10.1016/j.cllc.2024.02.006
Vancouver
Park JE, Hong KS, Choi SH, Lee SY, Shin KC, Jang JG, et al. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study. Clinical Lung Cancer. 2024;25(4):354-364. doi:10.1016/j.cllc.2024.02.006
BibTeX
@article{Park2024,
author = {Park, Ji Eun and Hong, Kyung Soo and Choi, Sun Ha and Lee, Shin Yup and Shin, Kyeong-Cheol and Jang, Jong Geol and Kwon, Yong Shik and Park, Sun Hyo and Choi, Keum-Ju and Jung, Chi Young and Eom, Jung Seop and Kim, Saerom and Seol, Hee Yun and Kim, Jehun and Kim, Insu and Park, Jin Han and Kim, Tae Hoon and Ahn, June Hong},
title = {Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study},
journal = {Clinical Lung Cancer},
year = {2024},
volume = {25},
number = {4},
pages = {354--364},
doi = {10.1016/j.cllc.2024.02.006}
}
EUVIMED